Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to determine the dose(s) of Ro 205-2349 which, when compared to
placebo, are efficacious, safe and tolerable in improving glycemic control in patients with
type 2 diabetes. Doses of 5 to 20 mg/day will be studied.